NCT04993755: An overdue trial by Transposon Therapeutics, Inc.
This trial is overdue. It was due to report 1 year, 6 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT04993755 |
|---|---|
| Title | A Phase 2a Study of TPN-101 in Patients With Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated With Hexanucleotide Repeat Expansion in the C9orf72 Gene (C9ORF72 ALS/FTD) |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 1, 2021 |
| Completion date | Sept. 1, 2023 |
| Required reporting date | Aug. 31, 2024, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 12, 2026 |
| Days late | 557 |